Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel Peptides

A pharmacology and composition technology, applied in the field of novel peptides or their derivatives or their salts, can solve the problems of unknown combination of angiotensin-converting enzyme fibroblasts and collagen adhesion promoting activities, etc., to restore tension and elasticity , Prevent the reduction of bonding ability and enhance the effect of bonding

Inactive Publication Date: 2015-08-19
ROHTO PHARM CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, no material having both angiotensin-converting enzyme inhibitory activity and adhesion-promoting activity between fibroblasts and collagen has been known so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel Peptides
  • Novel Peptides
  • Novel Peptides

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Embodiment 1: the preparation of peptide

[0088] 1-1. DLDVF (Asp-Leu-Asp-Val-Phe) peptide:

[0089] (1) Synthesis of peptides:

[0090] The title peptide was synthesized by a solid-phase synthesis method using the Fmoc method using an automatic peptide synthesizer (manufactured by Shimadzu Corporation: PSSM8). The specific procedure is as follows: First, after the C-terminal of Fmoc-Phe(1-Trt)-OH is bound to the resin for solid-phase synthesis, the protective group (Fmoc) is removed by piperidine treatment, and then the resin is neutralized. · After washing, introduce Fmoc-Val-OH into the N-terminus of Phe. Next, the protective group (Fmoc) was removed by piperidine treatment, and after neutralizing and washing the resin again, Fmoc-Asp(OtBu)-OH was introduced into the N-terminal of Val. Next, the protective group (Fmoc) was removed by piperidine treatment, and after neutralizing and washing the resin again, Fmoc-Leu-OH was introduced into the N-terminal of Asp. N...

Embodiment 2

[0103] Example 2: Determination of angiotensin-converting enzyme inhibitory activity

[0104] The angiotensin-converting enzyme inhibitory activity was measured using the various peptides prepared in Example 1 above.

[0105] Specifically, test solutions were prepared so that the concentration of each peptide was 1 mg / mL, and 1-fold, 10-fold, 100-fold, and 1000-fold dilutions were used to measure angiotensin-converting enzyme inhibitory activity. The angiotensin-converting enzyme inhibitory activity was evaluated by using the ACE Kit-WST kit (manufactured by Dojin Chemical Research Institute) to detect 3-hydroxybutyryl-Gly-Gly-Gly (3HB-GGG ), and measure the absorbance at 450 nm with a microplate reader. The ACE Kit-WST kit was used according to the attached protocol. The results are shown below.

[0106] [Table 1]

[0107] peptide

[0108] DLDV

[0109] As shown in the above results, it was revealed that any of the three test peptides exhibited high an...

Embodiment 3

[0110] Example 3: Evaluation of Fibroblast Adhesion to Collagen Coatings

[0111] The effect of promoting adhesion of fibroblasts to the collagen coating was evaluated using various peptides prepared in Example 1 above.

[0112] Specifically, first, 2 × 10 4 Fibroblasts (クラボウ: KF-4009) from human normal skin were inoculated at a concentration of cells / well. Next, 200 μl of Dulbecco’s modified Eagle’s medium (D-MEM; FCS10%·AB1%) diluted so that the concentration of each peptide was 5 μg / ml was added to each well. % carbon dioxide and 95% air environment for 20 hours of cultivation. On the other hand, cells to which 200 μl of D-MEM medium to which no peptide was added were prepared as a control. After 4 hours from the start of the culture, the supernatant of each well was washed with PBS, and the remaining amount of collagen coating adhered to and not washed was measured in each well using the Cell Counting Kit-8 kit (manufactured by Dojin Chemical Research Institute of Co., ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to View More

Abstract

The object of the present invention is to provide a kind of novel substance that has angiotensin-converting enzyme inhibitory activity and / or adhesion promoting activity between fibroblast and collagen, and described novel substance is a kind of formula (I) : Xaa1-Asp-Leu-Asp-Val-Xaa2 (SEQ ID NO: 1) [wherein Xaa1 and Xaa2 may or may not exist, and when present, each independently represents an arbitrary amino acid] Peptides or derivatives thereof, or salts thereof.

Description

technical field [0001] The present invention relates to a novel peptide having a specific amino acid sequence or a derivative thereof or a salt thereof. The novel peptides of the present invention or their derivatives or their salts can be used advantageously because they inhibit the activity of angiotensin-converting enzyme and also promote the adhesion between cells and collagen. Background technique [0002] Angiotensin-converting enzyme inhibitors are generally used widely for the treatment of hypertension and chronic heart failure. Angiotensin-converting enzyme inhibitors act on both the renin-angiotensin system of the pressor system and the kallikrein-kinin system of the depressor system in the living body, and exert the antihypertensive effect by dilating blood vessels, etc. Aspects are well known. Furthermore, it is also known that angiotensin-converting enzyme inhibitors have the effect of simultaneously reducing cardiac preload and afterload and improving cardiov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K8/64A61K38/00A61P9/10A61P9/12A61P17/00A61P43/00A61Q19/00C07K5/113C07K7/14A61K38/08
CPCC07K5/0806C07K5/0808C07K5/1021C07K7/06A61K38/08A61K8/64A61Q19/08A61P17/00A61P43/00A61P9/10A61P9/12
Inventor 阿部正通熊泽益德松本康助
Owner ROHTO PHARM CO LTD